Aptose Biosciences Files 8-K on June 20, 2025

Ticker: APTOF · Form: 8-K · Filed: Jun 20, 2025 · CIK: 882361

Sentiment: neutral

Topics: disclosure, financials, corporate-actions

Related Tickers: APTO

TL;DR

APTO filed an 8-K on 6/20/25 covering Reg FD and financials.

AI Summary

Aptose Biosciences Inc. filed an 8-K on June 20, 2025, reporting on events that occurred on the same date. The filing primarily concerns Regulation FD disclosures and includes financial statements and exhibits. The company, formerly known as Lorus Therapeutics Inc., is incorporated in Canada and has its principal executive offices in Toronto.

Why It Matters

This 8-K filing provides important updates and disclosures from Aptose Biosciences Inc. to the public, ensuring transparency regarding company events and financial information.

Risk Assessment

Risk Level: low — This filing is a routine 8-K for disclosures and exhibits, not indicating any immediate material adverse events.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on Regulation FD disclosures and to include financial statements and exhibits.

On what date was this 8-K report filed?

This 8-K report was filed on June 20, 2025.

What are some of the former names of Aptose Biosciences Inc.?

Aptose Biosciences Inc. was formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc.

In which jurisdiction is Aptose Biosciences Inc. incorporated?

Aptose Biosciences Inc. is incorporated in Canada.

What is the SIC code for Aptose Biosciences Inc.?

The Standard Industrial Classification (SIC) code for Aptose Biosciences Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 20, 2025 regarding Aptose Biosciences Inc. (APTOF).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing